Omi Japan Launches "Omi-PHR™ for Pharma" Development Package for Pharmaceutical Companies

Omi Japan Co., Ltd., the Japanese subsidiary of the Omi Group, which globally develops healthcare DX, has begun deploying "Omi-PHR™ for Pharma," a PHR development package for pharmaceutical companies. This package is based on Omi Japan's accumulated expertise in PHR development, with functions reorganized and reconstructed to meet the specific needs of pharmaceutical companies. It is designed for applications such as patient support, medication adherence support, patient-reported outcome (PRO) collection, patient support program (PSP) delivery, and real-world data (RWD) utilization. The package offers flexible customization to suit each company's target diseases, patient touchpoints, and operational policies. Planned additional features include alert functions for medication timing, medication management, PRO collection, vital and health data linkage from wearables, RWD collection and analysis, optional linkage with doctors and medical institutions, PSP delivery, and medication adherence support via questionnaires and chat. Omi Japan offers two provision models: full scratch PHR development for comprehensive customization and Omi-PHR™ OEM for rapid, cost-effective deployment using an existing PHR platform. Omi Japan has over 15 years of experience in medical and healthcare system development, having developed over 400 systems and introduced them to more than 10,000 medical institutions. The company will showcase "Omi-PHR™ for Pharma" at the Pharma IT & Digital Health Expo 2026, held from April 21-23, 2026, at Tokyo Big Sight (Booth 8G-07). They will also present on distributed clinical trial (DCT) DX solutions and applications of generative AI/AI agents. Omi Japan was established on February 1, 2013, with a capital of 20 million JPY, and is headquartered in Chuo-ku, Tokyo. The Omi Group, founded in 2012, has 940 employees across Vietnam, Japan, and Korea. Omi Japan holds ISO 9001:2015, ISO 13485, and JIS Q 27001:2023 certifications and is affiliated with JAHIS, LINK-J, MEJ, and WELCO Lab.